Events subsequent to the period end (Tables) - Cilo Cybin Holdings Limited [member]
|
12 Months Ended |
Mar. 31, 2025 |
Mar. 31, 2024 |
| IfrsStatementLineItems [Line Items] |
|
|
| Schedule of shareholder information |
ALPS
and Dr Tham are the Controlling Shareholders of Cilo Cybin, and the table below gives a breakdown of Cilo Cybin Shareholders’ respective
holdings in the Company as at 31 March 2025.
Schedule
of shareholder information
| Shareholder | |
Directly
| | |
Indirectly | | |
Total
number of Shares | | |
% of total | |
| | |
| | |
| | |
| | |
| |
| Dr Tham1 | |
| 28,762,252 | | |
| - | | |
| 28,762,252 | | |
| 40.5 | % |
| ALPS Global Holding Berhad | |
| 28,762,252 | | |
| - | | |
| 28,762,252 | | |
| 40.5 | % |
| Gabriel Theron1 | |
| 3,550,895 | | |
| - | | |
| 3,550,895 | | |
| 5.00 | % |
| Shyan & Van Huyssteen | |
| 2,840,716 | | |
| - | | |
| 2,840,716 | | |
| 4.00 | % |
| Public | |
| 7,101,791 | | |
| - | | |
| 7,101,791 | | |
| 10.00 | % |
| Total | |
| 71,017,906 | | |
| - | | |
| 71,017,906 | | |
| 100.0 | % |
Note:
| |
1. |
Dr
Tham and Gabriel Theron are the only directors of the Company with an equity interest in the Company. |
|
ALPS
and Dr Tham are the Controlling Shareholders of Cilo Cybin, and the table below gives a breakdown of Cilo Cybin Shareholders’ respective
holdings in the Company as at 31 March 2024:
Schedule
of shareholder information
Shareholder | |
| | |
Total
number of Shares | | |
%
of total | |
| | |
Directly | | |
Indirectly | | |
| | |
| |
| Dr Tham1 | |
| 28,762,252 | | |
| - | | |
| 28,762,252 | | |
| 45 | % |
| ALPS | |
| 28,762,252 | | |
| - | | |
| 28,762,252 | | |
| 45 | % |
| Gabriel Theron1 | |
| 3,550,895 | | |
| - | | |
| 3,550,895 | | |
| 5.56 | % |
| Shyan & Van Huyssteen | |
| 2,840,716 | | |
| - | | |
| 2,840,716 | | |
| 4.44 | % |
| Total | |
| 63,916,115 | | |
| - | | |
| 63,916,115 | | |
| 100.0 | % |
Note:
| 1. | Dr
Tham and Gabriel Theron are the only directors of the Company with an equity interest in
the Company. There were no changes to the number of shares held by Dr Tham or Gabriel Theron
between the year-end as at 31 March 2024 and the date of the approval of the annual financial
statements. |
| 2. | 7,101,791 Shares issued to members of the Public in terms of the successful IPO after year
ending 31 March 2024. |
|
| Schedule of profit or loss |
Schedule
of profit or loss
DETAIL STATEMENT OF PROFIT OR LOSS
| Figures in Rand | |
| | |
2025 | | |
2024 | |
| Other operating expenses | |
| | | |
| | | |
| | |
| Advertising | |
| | | |
| (108,689) | | |
| - | |
| Audit fees | |
| 11 | | |
| (756,784) | | |
| (207,379) | |
| Bank charges | |
| | | |
| (1,487) | | |
| (1,487) | |
| Consulting fees | |
| | | |
| (385,000) | | |
| - | |
| Depreciation | |
| 11 | | |
| (358,933) | | |
| - | |
| Employee costs | |
| 17 | | |
| (2,707,685) | | |
| - | |
| Legal fees | |
| | | |
| - | | |
| (191,986) | |
| Municipal expenses | |
| | | |
| (2,525) | | |
| - | |
| Public relations and marketing | |
| | | |
| (127,785) | | |
| (163,413) | |
| Rent | |
| | | |
| (20,027) | | |
| - | |
| Secretarial fees | |
| | | |
| (300,000) | | |
| - | |
| Subscriptions | |
| | | |
| (211,239) | | |
| - | |
| Training and development | |
| | | |
| (32,666) | | |
| - | |
| Travel - local | |
| | | |
| (1,500) | | |
| - | |
| Travel – overseas | |
| | | |
| (83,315) | | |
| - | |
| Operating loss | |
| 10 | | |
| (5,097,635) | | |
| (564,265) | |
| Investment income | |
| 11 | | |
| 4,828,827 | | |
| 1,064,093 | |
| Finance costs | |
| 12 | | |
| (316,908) | | |
| (44,394) | |
| (Loss) profit for the year | |
| | | |
| (585,715) | | |
| 455,434 | |
|
Schedule
of profit or loss
| |
|
Notes | |
| 12
months ended 31
March 2024 | | |
| 12
months ended 31
March 2023 | |
| |
|
| |
| | | |
| | |
| Revenue |
|
| |
| - | | |
| - | |
| Cost of sales |
|
| |
| - | | |
| - | |
| Gross
profit |
|
| |
| - | | |
| - | |
| Other income |
|
| |
| - | | |
| - | |
| Investment revenue |
|
| |
| 1,064,093 | | |
| - | |
| Audit fees |
|
| |
| (207,379) | | |
| (70,000) | |
| Legal fees |
|
| |
| (191,986) | | |
| (104,163) | |
| Public relations and marketing |
|
| |
| (163,413) | | |
| (337,220) | |
| Secretarial services |
|
| |
| - | | |
| (26,532) | |
| Bank charges |
|
| |
| (1,487) | | |
| (2,089) | |
| Operating
loss |
|
| |
| 499,829 | | |
| (540,004) | |
| Finance cost |
|
| |
| (44,394) | | |
| (12,000) | |
| Profit / (Loss) before taxation |
|
| |
| 455,435 | | |
| (552,004) | |
| Taxation |
|
| |
| - | | |
| - | |
| Profit / (Loss) for the
year |
|
| |
| 455,435 | | |
| (552,004) | |
| Other comprehensive income |
|
| |
| - | | |
| - | |
| Total
comprehensive profit / (loss) |
|
| |
| 455,435 | | |
| (552,004) | |
|
| Schedule of analysis of ordinary shareholders |
An
analysis of ordinary shareholders in the Company as at 31 March 2025 is set out below:
Schedule
of analysis of ordinary shareholders
| Shareholder spread | |
Number of shareholders | | |
% of total shareholdings | | |
Number of shares | | |
% of issued capital | |
| 1 - 1 000 | |
| 932 | | |
| 72 | % | |
| 203,990 | | |
| 0 | % |
| 1 001 - 10 000 | |
| 244 | | |
| 19 | % | |
| 896,181 | | |
| 1 | % |
| 10 001 - 100 000 | |
| 93 | | |
| 7 | % | |
| 3,332,163 | | |
| 5 | % |
| 1 00 001 - 1 000 000 | |
| 13 | | |
| 1 | % | |
| 2,669,457 | | |
| 4 | % |
| Over 1 000 000 | |
| 4 | | |
| 0 | % | |
| 63,916,115 | | |
| 90 | % |
| Total | |
| 1,286 | | |
| 100 | % | |
| 71,017,906 | | |
| 100 | % |
| Distribution of shareholders | |
Number of shareholders | | |
% of total shareholdings | | |
Number of shares | | |
% of issued capital | |
| Retail Shareholders | |
| 1,282 | | |
| 100 | % | |
| 7,101,791 | | |
| 10 | % |
| Directors and Prescribed Officers | |
| 2 | | |
| 0 | % | |
| 32,313,147 | | |
| 45 | % |
| Strategic Shareholders | |
| 1 | | |
| 0 | % | |
| 28,762,252 | | |
| 41 | % |
| Promoters | |
| 1 | | |
| 0 | % | |
| 2,840,716 | | |
| 4 | % |
| Total | |
| 1,286 | | |
| 100 | % | |
| 71,017,906 | | |
| 100 | % |
MAJOR
SHAREHOLDERS
| Beneficial Shareholders with a holding of greater than 5% of the issued shares | |
Number of shares | | |
% of issued capital | |
| Dr Tham | |
| 28,762,252 | | |
| 41 | % |
| ALPS Global Holding Berhad | |
| 28,762,252 | | |
| 41 | % |
| Gabriel Theron | |
| 3,550,895 | | |
| 5 | % |
| Total | |
| 61,075,399 | | |
| 87 | % |
|
|
| Schedule of Directors Emoluments |
Schedule
of Directors Emoluments
| | |
| Basic Salary | | |
| Total | |
| Executive | |
| | | |
| | |
| G.C Theron | |
| 1,620,000 | | |
| 1,620,000 | |
| R.M. Ledwaba | |
| 800,000 | | |
| 800,000 | |
| Total
Directors Emoluments | |
| 2,420,000 | | |
| 2,420,000 | |
|
|